Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL. - Álvarez-Corrales E; Moreno-Palomares R; Gómez-Escolar C; Martínez M; Moral-Pérez U; Laguna-Herrero M; Fuertes T; Estrada BS; Mur S; de Bonis A; Leiva M; Martínez-Martín N; et al. (Leukemia, 2026)